Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab versus placebo in immunoglobulin-dependent CIDP
NL-OMON48909Phase 2Active, not recruiting
- Sponsor
- UCB
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rozanolixizumab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by UCB. Started Feb 2020; status: active, not recruiting.
02
Drugs
rozanolixizumab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON48909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48909.